Results 31 to 40 of about 34,385 (232)

A risk stratification for systemic immunoglobulin light‐chain amyloidosis with renal involvement [PDF]

British Journal of Haematology, 2019
Renal involvement is found in about 70% of patients with systemic immunoglobulin light‐chain (AL) amyloidosis. However, there is no risk stratification system specialized for renal AL concerning patients’ survival. Galectin‐3 (Gal‐3) has been reported to
Ting Li, Xianghua Huang, Qingwen Wang, Liang Zhao, G. Ren, Wencui Chen, C. Zheng, Minlin Zhou, Qi Jiang, Ru Yin, Zhihong Liu   +10 more
semanticscholar   +2 more sources

A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. [PDF]

Kidney Int, 2021
Heybeli C, Bentall A, Wen J, Alexander MP, Buadi FK, Cosio FG, Dean PG, Dispenzieri A, Dingli D, El Ters M, Gertz MA, Hatem A, Kapoor P, Khamash H, Kourelis T, Kumar S, Lorenz EC, Mai M, Muchtar E, Murray DL, Prieto M, Schinstock CA, Stegall MD, Warsame R, Leung N.   +24 more
europepmc   +2 more sources

Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis. [PDF]

Current Opinion in Chemical Biology, 2023
N. Yan, G. Morgan, H. Petrassi, I. Wilson, J. Kelly   +4 more
semanticscholar   +2 more sources

First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. [PDF]

Blood, 2016
T. Sher, B. Fenton, A. Akhtar, M. Gertz
semanticscholar   +2 more sources

Modeling immunoglobulin light chain amyloidosis in Caenorhabditis elegans

Disease Models & Mechanisms
Margherita Romeo, Maria Monica Barzago, Alessandro Corbelli, Silvia Maglioni, Natascia Ventura, Carmina Natale, Andrea Conz, Mario Salmona, Giovanni Palladini, Mario Nuvolone, Fabio Fiordaliso, Giampaolo Merlini, Luisa Diomede   +12 more
doaj   +2 more sources

Venetoclax Plus CyBorD Induction Therapy and Venetoclax Maintenance Treatment for Immunoglobulin Light Chain Amyloidosis with t(11;14) Translocation. [PDF]

Curr Oncol
Garami G, Obajed Al-Ali O, Virga I, Gulyás A, Bedekovics J, Tornai I, Illés Á, Magyari F.   +7 more
europepmc   +2 more sources

Case Report: A missed diagnosis of cardiac amyloidosis using echocardiography due to immunoglobulin light chain amyloidosis with normal wall thickness in the early stage. [PDF]

Front Cardiovasc Med
Li X, Mu T, Deng Y, Zhang Y, Ti Y, Zhang L.   +5 more
europepmc   +2 more sources

A mouse model of cardiac immunoglobulin light chain amyloidosis reveals insights into tissue accumulation and toxicity of amyloid fibrils. [PDF]

Nat Commun
Martinez-Rivas G, Ayala MV, Bender S, Codo GR, Swiderska WK, Lampis A, Pedroza L, Merdanovic M, Sicard P, Pinault E, Richard L, Lavatelli F, Giorgetti S, Canetti D, Rinsant A, Kaaki S, Ory C, Oblet C, Pollet J, Naser E, Carpinteiro A, Roussel M, Javaugue V, Jaccard A, Bonaud A, Delpy L, Ehrmann M, Bridoux F, Sirac C.   +28 more
europepmc   +2 more sources

Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment

American journal of hematology/oncology, 2022
Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues.
M. Gertz
semanticscholar   +1 more source

Stem Cell Mobilization and Autologous Transplant for Immunoglobulin Light-Chain Amyloidosis. [PDF]

Hematol Oncol Clin North Am, 2020
Gertz MA, Schonland S.
europepmc   +3 more sources